Ampersand Capital Partners Invests in Syft Technologies

Ampersand Capital Partners Invests in Sterling Medical Devices

June 23, 2022

Medical Devices

Ampersand Capital Partners, a healthcare-focused private equity firm, made a growth equity investment in Sterling Medical Devices, a Moonachie, New Jersey-based provider of design, development and regulatory services for the medical device industry. The investment is intended to support Sterling’s continued growth and capability expansion across product development, software/electromechanical integration, and regulatory affairs.

Ampersand Capital Partners Invests in Magritek

March 18, 2021

Medical Devices

Ampersand Capital Partners made a minority growth investment in Magritek, a New Zealand-based maker of benchtop and portable NMR instruments. The investment will support Magritek's product expansion and market growth (including flow chemistry and bioprocess monitoring) while leveraging Ampersand's healthcare-focused private equity expertise.

Ampersand Capital Partners Acquires Specac Ltd.

March 13, 2024

Manufacturing

Ampersand Capital Partners, a Boston-based private equity firm focused on healthcare and life sciences, has acquired Specac Ltd., a UK-based designer and manufacturer of FTIR spectroscopy accessories and sample preparation solutions. The acquisition will support Specac's growth trajectory and leverage Ampersand's experience in life-sciences-oriented lab products and OEM channels.

Ampersand Capital Partners Makes Growth Investment in Lexington Medical

April 17, 2025

Medical Devices

Ampersand Capital Partners has made a strategic growth investment in Lexington Medical, a Bedford, Massachusetts-based designer and manufacturer of minimally invasive surgical stapling devices. The investment will support Lexington's product innovation, smart manufacturing initiatives, and global market expansion while bolstering the company's US-based manufacturing and talent base.

Ampersand Capital Partners Invests in BioEcho Life Sciences

March 1, 2022

Biotechnology

Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.